

DAFTAR PUSTAKA

- A, E., BR, A.E., SE, A.Z., 2019. Association between Dyslipidemia and Retinopati Diabetik in Type 2 Diabetic Patients. *J. Ophthalmic Stud.* 2, 1–6. <https://doi.org/10.16966/2639-152x.111>
- AAO staff, 2019. Retina and Vitreous: In :Basic and Clinical Science Course 2019-2020. American Academy of Ophthalmology.
- Alam, S., Hasan, M.K., Neaz, S., Hussain, N., Hossain, M.F., Rahman, T., 2021. Diabetes Mellitus: Insights from Epidemiology, Biochemistry, Risk Factors, Diagnosis, Complications and Comprehensive Management. *Diabetology* 2, 36–50. <https://doi.org/10.3390/diabetology2020004>
- Anindi Putri Harjanti, Yuliani, 2024. The Analysis Study of Association of Dyslipidemia and Retinopati Diabetik: A Comprehensive Systematic Review. *Indones. J. Gen.* 7, 55–77. <https://doi.org/10.70070/napbm925>
- Antar, S.A., Ashour, Nada A., Sharaky, M., Khattab, M., Ashour, Naira A., Zaid, R.T., Roh, E.J., Elkamhawy, A., Al-Karmalawy, A.A., 2023. Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments. *Biomed. Pharmacother.* 168, 115734. <https://doi.org/10.1016/j.biopha.2023.115734>
- Bailey, A., Mohiuddin, S.S., 2022. Biochemistry, High Density Lipoprotein. *StatPearls [Internet]. Treasure Isl.*
- Banday, M.Z., Sameer, A.S., Nissar, S., 2020. Pathophysiology of diabetes: An overview. *Avicenna J. Med.* 10, 174–188. https://doi.org/10.4103/ajm.ajm_53_20
- Bui, T.M., Wiesolek, H.L., Sumagin, R., 2020. ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis. *J. Leukoc. Biol.* 108, 787–799. <https://doi.org/10.1002/JLB.2MR0220-549R>
- Danek, D., Larsen, B., Anderson-Nelson, S., 2021. Non-proliferative Retinopati Diabetik. *Disease-a-Month* 67, 101139. <https://doi.org/10.1016/j.disamonth.2021.101139>
- Decker, S.O., Incamps, A., Sigl, A., Uhle, F., Bruckner, T., Heininger, A., Zimmermann, S., Hirtz, C., Weigand, M.A., Brenner, T., 2020. Soluble intercellular adhesion molecule- (sICAM-) 1, Thrombospondin-1, and vinculin for the identification of septic shock patients suffering from an invasive fungal infection. *Mediators Inflamm.* 2020. <https://doi.org/10.1155/2020/3470163>
- Denimal, D., Antioksidant and anti-inflammatory functions of high-density lipoprotein in type 1 and type 2 diabetes. *Antioxidants (Basel).* 2023 Dec 28;13(1):57. <https://doi.org/10.3390/antiox13010057>
- Edwiza, D.S., Angga Kartiwa, R., Rizky, M., Syamsunarno, A.A., Halim, A., Prahasta, A., 2022. Clinical Characteristics of Retinopati Diabetik In Diabetes Mellitus Patients in Tempuran District, Karawang Regency, West Java. *Ophthalmol. Indones.* 48, 48–58.
- Ekelund, C., Dereke, J., Nilsson, C., Landin-Olsson, M., 2024. Are soluble E-selectin, ICAM-1, and VCAM-1 potential predictors for the development of Retinopati Diabetik in young adults, 15-34 years of age? A Swedish prospective cohort study. *PLoS One* 19, 1–13. <https://doi.org/10.1371/journal.pone.0304173>
- Ezhilvendhan, K., Sathiyamoorthy, A., Prakash, B.J., Bhava, B.S., Shenoy, A., 2021. Association of Dyslipidemia with Retinopati Diabetik in Type 2 Diabetes Mellitus Patients. *J. Pharm. Bioallied Sci.* 13, S1062–S1067.

https://doi.org/10.4103/jpbs.jpbs_164_21

- Fadhlan Hatta Agustian, Yulia Wardany, 2024. Lipid Profile in Type 2 Diabetes Mellitus Patients with and without Retinopati Diabetik. Sumatera Med. J. 7, 132–140. <https://doi.org/10.32734/sumej.v7i3.15462>
- Ferrara, M., Loda, A., Coco, G., Grassi, P., Cestaro, S., Rezzola, S., Romano, V., Semeraro, F., 2023. Retinopati Diabetik: Soluble and Imaging Ocular Biomarkers. J. Clin. Med. 12. <https://doi.org/10.3390/jcm12030912>
- Ghonaim, M., El-Edel, R., 2015. Circulating cell adhesion molecules (sICAM-1 and sVCAM-1) and microangiopathy in diabetes mellitus. Ibmossina J. Med. Biomed. Sci. 07, 211–218. <https://doi.org/10.4103/1947-489x.210287>
- Gu, H.F., Ma, J., Gu, K.T., Brismar, K., 2013. Association of intercellular adhesion molecule 1 (ICAM1) with diabetes and diabetic nephropathy. Front. Endocrinol. (Lausanne). 3, 1–7. <https://doi.org/10.3389/fendo.2012.00179>
- Gui, F., You, Z., Fu, S., Wu, H., Zhang, Y., 2020. Endothelial Dysfunction in Retinopati Diabetik. Front. Endocrinol. (Lausanne). 11, 1–16. <https://doi.org/10.3389/fendo.2020.00591>
- Halim, A., Syumarti, S., Rini, M., Ratnaningsih, N., Iskandar, E., Sovani, I., Virgana, R., Dahlan, M.R., 2022. Prevalence and Associated Factors of Retinopati Diabetik in People with Type 2 Diabetes Attending Community Based Retinopati Diabetik Screening in Greater Bandung, Indonesia. Int. J. Retin. 5, 1. <https://doi.org/10.35479/ijretina.2022.vol005.iss001.172>
- Harini, I.M., Setyanto, M.R., Gumilas, N.S.A., Ernawati, D.A., 2022. Hubungan antara Profil Lipid dengan Kejadian Retinopati Diabetika pada Pasien Diabetes Melitus Tipe 2 di Fasilitas Kesehatan Tingkat Pertama Klinik Tanjung Purwokerto. J. Kesehat. Andalas 11, 14. <https://doi.org/10.25077/jka.v11i1.1932>
- Harley, O., Hertanto, M., Sembiring, S.B., Yustiarini, I., Susilo, T., Dharma, A.G., Elviosa, E., Ichsan, A.M., Kartasasmita, A.S., Harley, O., 2024. GUIDELINES FOR THE DIAGNOSIS AND MANAGEMENT OF RETINOPATI DIABETIK AND DIABETIC MACULAR EDEMA IN INDONESIA Correspondence to : 007.
- Ishibashi, T., Kaneko, H., Matsuoka, S., Suzuki, Y., Ueno, K., Ohno, R., Okada, A., Fujii, K., Michihata, N., Jo, T., Takeda, N., Morita, H., Node, K., Yasunaga, H., Komuro, I., 2023. HDL cholesterol and clinical outcomes in diabetes mellitus. Eur. J. Prev. Cardiol. 30, 646–653. <https://doi.org/10.1093/eurjpc/zwad029>
- Jain, A., Saxena, S., Khanna, V.K., Shukla, R.K., Meyer, C.H., 2013. Status of serum VEGF and ICAM-1 and its association with external limiting membrane and inner segment-outer segment junction disruption in type 2 diabetes mellitus. Mol. Vis. 19, 1760–1767.
- Kapa, M., Koryciarz, I., Kustosik, N., Jurowski, P., Pniakowska, Z., 2024. Modern Approach to Retinopati Diabetik Diagnostics. Diagnostics 14. <https://doi.org/10.3390/diagnostics14171846>
- Karimi, Z., Kahe, F., Jamil, A., Marszalek, J., Ghanbari, A., Afarideh, M., Khajeh, E., Noshad, S., Esteghamati, A., Chi, G., 2018. Intercellular adhesion molecule-1 in diabetic patients with and without microalbuminuria. Diabetes Metab. SynRD. Clin. Res. Rev. 12, 365–368. <https://doi.org/10.1016/j.dsx.2017.12.028>
- Kontush, A., Lindahl, M., Lhomme, M., Calabresi, L., Chapman, M.J., Davidson, W.S., 2015. Structure of HDL: Particle subclasses and molecular components, Handbook of Experimental Pharmacology. https://doi.org/10.1007/978-3-319-09665-0_1
- Kosmas, C.E., Martinez, I., Sourlas, A., Bouza, K. V., Campos, F.N., Torres, V., Montan, P.D., Guzman, E., 2018. High-density lipoprotein (HDL) functionality

- and its relevance to atherosclerotic cardiovascular disease. *RDugs Context* 7, 1–9. <https://doi.org/10.7573/dic.212525>
- Kropp, M., Golubnitschaja, O., Mazurakova, A., Koklesova, L., Sargheini, N., Vo, T.T.K.S., de Clerck, E., Polivka, J., Potuznik, P., Polivka, J., Stetkarova, I., Kubatka, P., Thumann, G., 2023. Retinopati Diabetik as the leading cause of blindness and early predictor of cascading complications—risks and mitigation. *EPMA J.* 14, 21–42. <https://doi.org/10.1007/s13167-023-00314-8>
- Li, C., Wang, L., Feng, D., Bian, X., You, H., Liang, C., Wang, J., 2025. A cohort study on the risk of Retinopati Diabetik in type 2 diabetes patients with serum TG/HDL-C ratio. *Prim. Care Diabetes* 19, 195–200. <https://doi.org/10.1016/j.pcd.2025.01.005>
- Liu, Z., Shao, M., Ren, J., Qiu, Y., Li, S., Cao, W., 2022. Association Between Increased Lipid Profiles and Risk of Retinopati Diabetik in a Population-Based Case-Control Study. *J. Inflamm. Res.* 15, 3433–3446. <https://doi.org/10.2147/JIR.S361613>
- M. Mounirou, B., Adam, N., H. Yakoura, A., M. Aminou, M., Liu, Y., Tan, L., 2022. Retinopati Diabetik: An overview of treatments. *Indian J. Endocrinol. Metab.* 26, 111. https://doi.org/10.4103/ijem.ijem_480_21
- Mahabadi, N., Khalili, Y. Al, 2023. Neuroanatomy, Retina. *StatPearls* [Internet].
- Maheshwari, S.Y., Kumar, S., Sinha, A.H., Kumar, M., 2023. Retinopati Diabetik: A Pharmacological Consideration. *Cureus* 15. <https://doi.org/10.7759/cureus.46842>
- Ojo, O.A., Ibrahim, H.S., Rotimi, D.E., Ogunlakin, A.D., Ojo, A.B., 2023. Diabetes mellitus: From molecular mechanism to pathophysiology and pharmacology. *Med. Nov. Technol. Devices* 19, 100247. <https://doi.org/10.1016/j.medntd.2023.100247>
- Parveen, N., Ahmad, A., Bukhari, S., Khan, Z., Mahmood, R., Khan, Q., 2021. Association of Retinopati Diabetik with dyslipidemia : a multicenter study Association of Retinopati Diabetik with dyslipidemia : a multicenter study 4, 21–24.
- Purnama, R.F.N., 2023. Retinopati Diabetik : Manifestasi Klinis, Diagnosis, Tatalaksana dan Pencegahan. *Lomb. Med. J.* 2, 39–42. <https://doi.org/10.29303/Imj.v2i1.2410>
- Ramos, T.N., Bullard, D.C., Barnum, S.R., 2014. ICAM-1: Isoforms and Phenotypes. *J. Immunol.* 192, 4469–4474. <https://doi.org/10.4049/jimmunol.1400135>
- Reddy, S.K., Devi, V., Seetharaman, A.T.M., Shailaja, S., Bhat, K.M.R., Gangaraju, R., Upadhy, D., 2024. Cell and molecular targeted therapies for Retinopati Diabetik. *Front. Endocrinol. (Lausanne)*. 15, 1–16. <https://doi.org/10.3389/fendo.2024.1416668>
- Robert, J., Osto, E., von Eckardstein, A., 2021. The Endothelium Is Both a Target and a Barrier of HDL's Protective Functions. *Cells* 10(5), 1041. <https://doi.org/10.3390/cells10051041>
- Romero-Aroca, P., Verges, R., Pascual-Fontanilles, J., Valls, A., Franch, J., Barrot, J., Mundet, X., La Torre, A., Moreno, A., Sagarra, R., Basora, J., Garcia-Curto, E., Baget-Bernaldiz, M., 2023. Effect of Lipids on Retinopati Diabetik in a Large Cohort of Diabetic Patients after 10 Years of Follow-Up. *J. Clin. Med.* 12. <https://doi.org/10.3390/jcm12206674>
- Sadat, T., Ghavami, T., Pashizeh, F., Furkan Ercisli, M., Alaei, F., 2021. Retinopati Diabetik: mechanisms, and upcoming biomarkers. *Cent. Asian J. Med. Pharm. Sci. Innov.* 3, 131–142.

- Sanyaolu, A., Marinkovic, A., Prakash, S., Williams, M., Dixon, Y., Okorie, C., Orish, V.N., Izurieta, R., 2023. Diabetes mellitus: An overview of the types, prevalence, comorbidity, complication, genetics, economic implication, and treatment. *World J. Meta-Analysis* 11, 134–143. <https://doi.org/10.13105/wjma.v11.i5.134>
- Shukla, U. V., Tripathy, K., 2023. Retinopati Diabetik. *StatPearls* [Internet].
- Simó-Servat, O., Simó, R., Hernández, C., 2016. Circulating Biomarkers of Retinopati Diabetik: An Overview Based on Physiopathology. *J. Diabetes Res.* 2016. <https://doi.org/10.1155/2016/5263798>
- Tan, T.E., Wong, T.Y., 2023. Retinopati Diabetik: Looking forward to 2030. *Front. Endocrinol. (Lausanne)*. 13, 1–8. <https://doi.org/10.3389/fendo.2022.1077669>
- Theofilis, P., Sagris, M., Oikonomou, E., et al. Inflammatory mechanisms contributing to endothelial dysfunction. *Biomedicines*. 2021;9(7):781. <https://doi.org/10.3390/biomedicines9070781>
- Victor, A.A., Gondhowiardjo, T.D., Dharma, R., Jusman, S.W.A., YanRDi, V.R., Yuneta, R., Yuriza, R.E.P., 2020. Intercellular adhesive molecule-1 (Icam-1) in proliferative Retinopati Diabetik. *Asian J. Ophthalmol.* 17, 120–127. <https://doi.org/10.35119/asjoo.v17i1.516>
- Waheed, N., Kashani, A., 2018. Retinal Imaging and Diagnostics :Optical Coherence Tomography. *Ryan's Retina*.
- Wei, L., Sun, X., Fan, C., Li, R., Zhou, S., Yu, H., 2022. The pathophysiological mechanisms underlying Retinopati Diabetik. *Front. Cell Dev. Biol.* 10, 1–12. <https://doi.org/10.3389/fcell.2022.963615>
- Wilkinson, M.J., 2018. Anatomy of the human orbit. *Oper. Tech. Otolaryngol. - Head Neck Surg.* 29, 186–192. <https://doi.org/10.1016/j.otot.2018.10.002>
- Witkowska, A.M., Borawska, M.H., 2004. Soluble intercellular adhesion molecule-1 (sICAM-1): An overview. *Eur. Cytokine Netw.* 15, 91–98.
- Wright, W.S., Eshaq, R.S., Lee, M., Kaur, G., Harris, N.R., 2020. Retinal physiology and circulation: Effect of diabetes. *Compr. Physiol.* 10, 933–974. <https://doi.org/10.1002/cphy.c190021>
- Xiao, X., Han, Y., Li, Q., Zheng, D., Cheng, C.Y., Ni, Y., 2024. Exploring the evolving function of soluble intercellular adhesion molecule-1 in junction dynamics during spermatogenesis. *Front. Endocrinol. (Lausanne)*. 14, 1–14. <https://doi.org/10.3389/fendo.2023.1281812>
- Xie, Z., Xiao, X., 2022. Novel biomarkers and therapeutic approaches for Retinopati Diabetik and nephropathy: Recent progress and future perspectives. *Front. Endocrinol. (Lausanne)*. 13, 1–12. <https://doi.org/10.3389/fendo.2022.1065856>
- Xu, W., Xu, X., Zhang, M., Sun, C., 2024. Association between HDL cholesterol with Retinopati Diabetik in diabetic patients: a cross-sectional retrospective study. *BMC Endocr. Disord.* 24, 1–8. <https://doi.org/10.1186/s12902-024-01599-0>
- Yao, Y., Du, J., Li, R., Zhao, L., Luo, N., Zhai, J.Y., Long, L., 2019. Association between ICAM-1 level and Retinopati Diabetik: A review and meta-analysis. *Postgrad. Med. J.* 95, 162–168. <https://doi.org/10.1136/postgradmedj-2018-136102>
- Zaini, L.M., Kartasasmitha, A.S., Gondhowiardjo, T.D., Syukri, M., Mulya, P.N., 2024. Clinical characteristics and knowledge of Retinopati Diabetik patients at a tertiary hospital in Aceh, Indonesia. *African Vis. Eye Heal.* 83, 1–8. <https://doi.org/10.4102/AVEH.V83i1.949>
- Zhang, C., Lin, W., Xu, Q., Li, H., Xu, C., Ma, X., Hao, M., Kuang, H., 2023. Association between high-density lipoprotein cholesterol to apolipoprotein A ratio and Retinopati Diabetik: A cross-sectional study. *J. Diabetes Complications*

37, 108471. <https://doi.org/10.1016/j.jdiacomp.2023.108471>